New biomarker identifies patients with aggressive lymphoma who don't respond to precision therapy
A new biomarker discovered by a team that includes researchers from Penn Medicine identifies patients with an aggressive form of lymphoma unlikely to respond to the targeted treatment ibrutinib. It's a clinically actionable ...
Dec 7, 2020
0
2